The ‘ELAD’ Study, Evaluating Liraglutide in Alzheimer’s Disease, is evaluating the drug Liraglutide, that is currently used to treat diabetes patients by increasing their production of insulin.

Researchers know as well that insulin is an important part of the signalling process between nerve cells – and nerve cells are most at risk from the damage caused by dementia.

How does it work?

The exact nature of insulin and how it takes part in nerve communication is still being discovered, but researchers are hopeful that Liraglutide may help prevent nerve damage in patients.

Having completed early studies, ‘Join dementia research’ is now being used to recruit Alzheimer’s Disease patients who can participate in testing.

Two groups of volunteers will be formed, with one assigned the Liraglutide and the other a placebo so that researchers can compare the results.
Scans of the brain will be taken so that any changes can immediately be detected.

Staff are hopeful that if a positive response to the drug can be shown, this could be a helpful new treatment for people living with dementia.

Get Involved

If you are between fifty and eighty-five, with a diagnosis of Alzheimer’s Disease, and have a carer who can work with you as a study partner, you might be suitable to the study.

To see if you might be a match for the study, please sign up by using the button on the right, to share your information with our researchers.

You will be able to participate in a study that will hopefully lead to better treatments for dementia patients.